NASDAQ:SYRS Syros Pharmaceuticals (SYRS) Stock Forecast, Price & News $3.98 +0.03 (+0.76%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$3.89▼$4.0350-Day Range$3.35▼$4.1252-Week Range$2.42▼$6.95Volume42,810 shsAverage Volume93,005 shsMarket Capitalization$82.43 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Syros Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside239.2% Upside$13.50 Price TargetShort InterestHealthy3.83% of Float Sold ShortDividend StrengthN/ASustainability-0.49Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$31,436 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.41) to ($4.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector392nd out of 968 stocksPharmaceutical Preparations Industry167th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.50, Syros Pharmaceuticals has a forecasted upside of 239.2% from its current price of $3.98.Amount of Analyst CoverageSyros Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.83% of the float of Syros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Syros Pharmaceuticals has recently decreased by 0.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyros Pharmaceuticals has received a 75.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Syros Pharmaceuticals is -0.49. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for SYRS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,436.00 in company stock.Percentage Held by Insiders10.45% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.29% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($4.41) to ($4.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Syros Pharmaceuticals (NASDAQ:SYRS) StockSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Read More SYRS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRS Stock News HeadlinesAugust 10, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Syros Pharmaceuticals (SYRS)August 9, 2023 | markets.businessinsider.comSyros Pharmaceuticals (SYRS) Gets a Buy from H.C. WainwrightSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 9, 2023 | finance.yahoo.comQ2 2023 Syros Pharmaceuticals Inc Earnings CallAugust 8, 2023 | finance.yahoo.comSyros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue EstimatesAugust 8, 2023 | finance.yahoo.comSyros Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateAugust 1, 2023 | finance.yahoo.comSyros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023July 24, 2023 | benzinga.comPfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood DisordersSeptember 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.July 21, 2023 | finance.yahoo.comPfizer to end license deal with Syros for blood disorder therapiesJuly 6, 2023 | msn.comSyros Pharmaceuticals (SYRS) Price Target Increased by 22.53% to 164.73June 8, 2023 | finance.yahoo.comSyros to Present at Sidoti June 2023 Virtual Small-Cap ConferenceMay 25, 2023 | finance.yahoo.comSyros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual MeetingMay 25, 2023 | finance.yahoo.comOne Syros Pharmaceuticals Insider Raised Stake By 212% In Previous YearMay 25, 2023 | finance.yahoo.comOne Syros Pharmaceuticals Insider Raised Stake By 212% In Previous Year \May 23, 2023 | fool.comSyros Pharmaceuticals (NASDAQ: SYRS)May 13, 2023 | finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call TranscriptMay 12, 2023 | msn.comJMP Securities Maintains Syros Pharmaceuticals (SYRS) Market Outperform RecommendationMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Syros Pharmaceuticals (SYRS) Buy RecommendationMay 10, 2023 | finance.yahoo.comQ1 2023 Syros Pharmaceuticals Inc Earnings CallMay 10, 2023 | finance.yahoo.comSyros Reports First Quarter 2023 Financial Results and Provides a Corporate UpdateMay 9, 2023 | finance.yahoo.comSyros to Present at JMP Securities 2023 Life Sciences ConferenceMay 8, 2023 | finance.yahoo.comImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar?May 3, 2023 | finance.yahoo.comSyros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023March 6, 2023 | finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call TranscriptMarch 5, 2023 | benzinga.comSyros Pharmaceuticals Stock (NASDAQ:SYRS), Guidance and ForecastMarch 4, 2023 | seekingalpha.comSyros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Call TranscriptSee More Headlines Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRS Company Calendar Last Earnings8/08/2023Today9/22/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS CUSIPN/A CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees117Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.50 High Stock Price Forecast$15.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+241.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($5.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,650,000.00 Net MarginsN/A Pretax Margin-1,065.37% Return on Equity-108.32% Return on Assets-51.69% Debt Debt-to-Equity Ratio0.56 Current Ratio5.38 Quick Ratio5.38 Sales & Book Value Annual Sales$14.88 million Price / Sales5.50 Cash FlowN/A Price / Cash FlowN/A Book Value$6.32 per share Price / Book0.63Miscellaneous Outstanding Shares20,710,000Free Float18,546,000Market Cap$81.80 million OptionableOptionable Beta1.59 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Nancy A. Simonian M.D. (Age 62)Pres, CEO & Director Comp: $955.39kDr. Richard A. Young Ph.D. (Age 69)Scientific Founder, Member of Scientific Advisory Board & Director Comp: $108.37kDr. Eric R. Olson Ph.D. (Age 65)Chief Scientific Officer Comp: $667.6kDr. David A. Roth M.D. (Age 60)Chief Medical Officer Comp: $679.52kDr. James E. Bradner M.D. (Age 51)Founder Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Jason Haas (Age 55)Chief Financial Officer Ms. Karen Hunady M.S.Director of Corp. Communications & Investor RelationsMr. Gerald E. Quirk Esq. (Age 55)J.D., Chief Legal & Compliance Officer Ms. Lisa RobertsVP of HRMore ExecutivesKey CompetitorsLifeVantageNASDAQ:LFVNDURECTNASDAQ:DRRXShattuck LabsNASDAQ:STTKIncannex HealthcareNASDAQ:IXHLNkartaNASDAQ:NKTXView All CompetitorsInsiders & InstitutionsShay Capital LLCBought 12,317 shares on 8/14/2023Ownership: 0.128%BlackRock Inc.Bought 22,910 shares on 8/11/2023Ownership: 1.019%Geode Capital Management LLCBought 46,784 shares on 8/11/2023Ownership: 0.627%ExodusPoint Capital Management LPSold 3,157 shares on 8/11/2023Ownership: 0.572%Simplex Trading LLCSold 600 shares on 8/4/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SYRS Stock - Frequently Asked Questions Should I buy or sell Syros Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares. View SYRS analyst ratings or view top-rated stocks. What is Syros Pharmaceuticals' stock price forecast for 2023? 4 brokers have issued 12 month price objectives for Syros Pharmaceuticals' shares. Their SYRS share price forecasts range from $11.00 to $15.00. On average, they anticipate the company's share price to reach $13.50 in the next year. This suggests a possible upside of 241.8% from the stock's current price. View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts. How have SYRS shares performed in 2023? Syros Pharmaceuticals' stock was trading at $3.59 at the start of the year. Since then, SYRS stock has increased by 10.0% and is now trading at $3.95. View the best growth stocks for 2023 here. When is Syros Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our SYRS earnings forecast. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) posted its earnings results on Tuesday, August, 8th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by $0.19. The firm earned $2.83 million during the quarter, compared to analysts' expectations of $3.17 million. When did Syros Pharmaceuticals' stock split? Syros Pharmaceuticals's stock reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO? 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE). When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.02%), Geode Capital Management LLC (0.63%), ExodusPoint Capital Management LP (0.57%), LPL Financial LLC (0.46%), Shay Capital LLC (0.13%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David Roth, Eric R Olson, Richard A Young and Timothy Tyson. View institutional ownership trends. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $3.95. How much money does Syros Pharmaceuticals make? Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $81.80 million and generates $14.88 million in revenue each year. The company earns $-94,650,000.00 in net income (profit) each year or ($5.53) on an earnings per share basis. How many employees does Syros Pharmaceuticals have? The company employs 117 workers across the globe. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com. This page (NASDAQ:SYRS) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.